Viromed Medical AG Converts to Registered Shares to Enhance Shareholder Transparency

Viromed Medical AG, a medical technology company specializing in cold plasma technology, is converting its share capital from bearer shares to registered shares following a resolution passed by the Annual General Meeting on July 29, 2025. The resolution with corresponding amendments to the Articles of Association was entered in the company's commercial register on August 8, 2025, making it effective. This conversion represents a significant structural change for the company, which has been listed on the stock exchange since October 2022.

The conversion process involves deregistering all 21,250,000 bearer shares held in collective custody under ISIN DE000A3MQR65 by custodian banks and Clearstream Banking AG, Frankfurt am Main, on the evening of January 16, 2026, designated as the Record Day. Shareholders will receive one new registered share for each previous bearer share, with each share representing a proportionate amount of the share capital of €1.00 and carrying the new ISIN DE000A40VZN7. According to the company's Articles of Association, the right to individual certification is excluded, with the share capital certified in a global certificate deposited with Clearstream Banking AG.

Trading of the existing bearer shares concluded on January 14, 2026, with the new registered shares listed on the stock exchange under the new ISIN beginning January 15, 2026. This transition maintains continuity in market trading while implementing the structural change. The conversion does not affect shareholders' proportional ownership of the company's share capital or the rights associated with their shares. Importantly, it does not restrict shareholders' ability to sell their shares, as the transfer of registered shares does not require company approval, preserving liquidity and market functionality.

The shift to registered shares enables increased transparency and direct communication with shareholders, allowing the company to maintain an accurate shareholder register and engage more effectively with its investor base. This move aligns with corporate governance trends emphasizing shareholder engagement and transparency. Viromed Medical AG, through its wholly owned subsidiary Viromed Medical GmbH, focuses on distributing innovative cold plasma technology for medical applications, serving a broad customer base in the DACH region and beyond. The company aims to advance cold plasma technology in medicine and realize corresponding growth potential in coming years. Additional information about the company is available at https://www.viromed-medical-ag.de.